{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:52:11Z","timestamp":1793040731753,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AbbVie Italy","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00415-019-09337-6","type":"journal-article","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T11:02:45Z","timestamp":1558954965000},"page":"2164-2176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Motor and non-motor outcomes in patients with advanced Parkinson\u2019s disease treated with levodopa\/carbidopa intestinal gel: final results of the GREENFIELD observational study"],"prefix":"10.1007","volume":"266","author":[{"given":"Leonardo","family":"Lopiano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Modugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Marano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Sensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Meco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Solla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziano","family":"Gusmaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Tamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Quatrale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zangaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Bentivoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Eleopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Gualberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9944-3810","authenticated-orcid":false,"given":"Gabriella","family":"Melzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,27]]},"reference":[{"issue":"2","key":"9337_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1586\/erp.11.106","volume":"12","author":"P Martinez-Martin","year":"2012","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ (2012) Quality of life and burden in caregivers for patients with Parkinson\u2019s disease: concepts, assessment and related factors. Expert Rev Pharmacoecon Outcomes Res 12(2):221\u2013230","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"9337_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-0037-1602423","volume":"37","author":"EM Freitas","year":"2017","unstructured":"Freitas EM, Hess CW, Fox SH (2017) Motor complications of dopaminergic medications in Parkinson\u2019s disease. Semin neurol 37(2):147\u2013157","journal-title":"Semin neurol"},{"key":"9337_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.parkreldis.2014.11.002","volume":"21","author":"MC Altavista","year":"2015","unstructured":"Altavista MC, Cassetta E, Brusa L, Viselli F, Denaro A, Ventriglia M, Pasqualetti P, Peppe A (2015) Wearing-off detection in clinical practice: the wearing off real practice key (WORK-PD) study in parkinson\u2019s disease. Parkins Rel Disord 21:95\u2013100","journal-title":"Parkins Rel Disord"},{"issue":"6","key":"9337_CR4","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/mds.27340","volume":"33","author":"A Antonini","year":"2018","unstructured":"Antonini A, Moro E, Godeiro C, Reichmann H (2018) Medical and surgical management of advanced Parkinson's disease. Mov Disord 33(6):900\u2013908.","journal-title":"Mov Disord"},{"key":"9337_CR5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1208\/s12248-012-9439-1","volume":"15","author":"D Nyholm","year":"2013","unstructured":"Nyholm D, Odin P, Johansson A, Chatamra K, Locke C, Dutta S, Othman AA (2013) Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease patients. AAPS J 15:316\u2013323","journal-title":"AAPS J"},{"issue":"8","key":"9337_CR6","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00702-018-1906-0","volume":"125","author":"A Antonini","year":"2018","unstructured":"Antonini A, Nitu B (2018) Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. J Neural Transm 125(8):1131\u20131135. \n                    https:\/\/doi.org\/10.1007\/s00702-018-1906-0","journal-title":"J Neural Transm"},{"key":"9337_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40263-016-0336-5","volume":"30","author":"K Wirefeldt","year":"2016","unstructured":"Wirefeldt K, Odin P, Nyholm D (2016) Levodopa-carbidopa intestinal gel in patients with Parkinson\u2019s disease: a systematic review. CNS Drugs 30:381\u2013404","journal-title":"CNS Drugs"},{"issue":"2","key":"9337_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A, for the LCIG Horizon Study Group (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13(2):141\u2013149","journal-title":"Lancet Neurol"},{"issue":"4","key":"9337_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.26123","volume":"30","author":"HH Fernandez","year":"2015","unstructured":"Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord 30(4):500\u2013509","journal-title":"Mov Disord"},{"issue":"1","key":"9337_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/JPD-140456","volume":"5","author":"JT Slevin","year":"2015","unstructured":"Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, Chatamra K, Benesh J (2015) Long-term safety and maintenance of efficacy of Levodopa-Carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson\u2019s disease patients. J Parkinsons Dis 5(1):165\u2013174","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"9337_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/mds.26528","volume":"31","author":"A Antonini","year":"2016","unstructured":"Antonini A, Fung VSC, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA (2016) Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson\u2019s disease patients. Mov Disord 31(4):530\u2013537. \n                    https:\/\/doi.org\/10.1002\/mds.26528","journal-title":"Mov Disord"},{"issue":"6","key":"9337_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/ane.12483","volume":"133","author":"JF Timpka","year":"2016","unstructured":"Timpka JF, Fox T, Fox K, Honig H, Odin P, Martinez-Martin P, Antonini A, Chauduri RK (2016) Improvement of dyskinesias with l-dopa infusion in advanced Parkinson\u2019s disease. Acta Neurol Scand 133(6):451\u2013458. \n                    https:\/\/doi.org\/10.1111\/ane.12483","journal-title":"Acta Neurol Scand"},{"issue":"7","key":"9337_CR13","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s12325-017-0571-2","volume":"34","author":"R Kruger","year":"2017","unstructured":"Kruger R, Lingor P, Doskas T, Henselmans JML, Danielsen EH, de Fabregues O, Stefani A, Sensken SC, Parra JC, Onuk K, Yegin A, Antonini A (2017) An observational study of the effect of levodopa-carbidopa intestinal gel on activities of daily living and quality of life in advanced Parkinson\u2019s disease patients. Adv Ther 34(7):1741\u20131752. \n                    https:\/\/doi.org\/10.1007\/s12325-017-0571-2","journal-title":"Adv Ther"},{"issue":"3","key":"9337_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.parkreldis.2014.12.012","volume":"21","author":"A Antonini","year":"2015","unstructured":"Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, GLORIA study investigators, and coordinators (2015) Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkins Rel Disord 21(3):231\u2013235. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2014.12.012","journal-title":"Parkins Rel Disord"},{"issue":"8","key":"9337_CR15","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.parkreldis.2015.05.014","volume":"21","author":"M Buongiorno","year":"2015","unstructured":"Buongiorno M, Antonelli F, C\u00e1mara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J, Calopa M, Pascual-Sedano B, Campolongo A, Valldeoriola F, Tolosa E, Kulisevsky J, Mart\u00ed MJ (2015) Long-term response to continuous duodenal infusion of levodopa\/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkins Rel Disord 21(8):871\u2013876. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2015.05.014","journal-title":"Parkins Rel Disord"},{"issue":"6","key":"9337_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s10072-013-1612-5","volume":"35","author":"BA Pickut","year":"2014","unstructured":"Pickut BA, van der Linden C, Dethy S, Van De Maele H, de Beyl DZ (2014) Intestinal levodopa infusion: the Belgian experience. Neurol Sci 35(6):861\u2013866. \n                    https:\/\/doi.org\/10.1007\/s10072-013-1612-5","journal-title":"Neurol Sci"},{"issue":"11","key":"9337_CR17","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00702-013-1026-9","volume":"120","author":"A Antonini","year":"2013","unstructured":"Antonini A, Odin P, Lopiano L, Tomantschger V, Pacchetti C, Pickut B, Gasser UE, Calandrella D, Mancini F, Zibetti M, Minafra B, Bertaina I, De Deyn P, Cras C, Wolf E, Spielberger S, Poewe W (2013) Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm 120(11):1553\u20131558. \n                    https:\/\/doi.org\/10.1007\/s00702-013-1026-9","journal-title":"J Neural Transm"},{"issue":"8","key":"9337_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1468-1331.2012.03679.x","volume":"19","author":"D Nyholm","year":"2012","unstructured":"Nyholm D, Klangemo K, Johansson A (2012) Levodopa\/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol. 19(8):1079\u20131085. \n                    https:\/\/doi.org\/10.1111\/j.1468-1331.2012.03679.x","journal-title":"Eur J Neurol."},{"issue":"2","key":"9337_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/WNF.0b013e3180ed449f","volume":"31","author":"D Nyholm","year":"2008","unstructured":"Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM (2008) Enteral levodopa\/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 31(2):63\u201373. \n                    https:\/\/doi.org\/10.1097\/WNF.0b013e3180ed449f","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"9337_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/ene.12309","volume":"21","author":"M Zibetti","year":"2014","unstructured":"Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D, De Angelis C, Rizzone M, Lopiano L (2014) Levodopa\/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. Eur J Neurol 21(2):312\u2013318","journal-title":"Eur J Neurol"},{"key":"9337_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.parkreldis.2016.05.015","volume":"29","author":"A Merola","year":"2016","unstructured":"Merola A, Espay AJ, Romagnolo A, Bernardini A, Rizzi L, Rosso M, Espay KJ, Zibetti M, Lanotte M, Lopiano L (2016) Advanced therapies in Parkinson's disease: long-term retrospective study. Parkinsonism Relat Disord. 29:104\u2013108. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2016.05.015","journal-title":"Parkinsonism Relat Disord."},{"issue":"11","key":"9337_CR22","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s10072-016-2664-0","volume":"37","author":"L Lopiano","year":"2016","unstructured":"Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Cannas A, Gusmaroli G, Tamma F, Mancini F, Quatrale R, Costanzo AM, Gualberti G, Melzi G, di Luzio Paparatti U, Antonini A (2016) Motor outcomes in patients with advanced Parkinson's disease treated with levodopa\/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study. Neurol Sci. 37(11):1785\u20131792","journal-title":"Neurol Sci"},{"issue":"6","key":"9337_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00702-013-1153-3","volume":"121","author":"M Sensi","year":"2014","unstructured":"Sensi M, Preda F, Trevisani L, Contini E, Gragnaniello D, Capone JG, Sette E, Golfr\u00e8 Andreasi N, Tugnoli V, Tola MR, Quatrale R (2014) Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. J Neural Transm 121(6):633\u2013642","journal-title":"J Neural Transm"},{"key":"9337_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirto\u0161ek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P, GLORIA study co-investigators (2017) Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism Relat Disord. 45:13\u201320. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2017.09.018","journal-title":"Parkinsonism Relat Disord"},{"key":"9337_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jns.2017.12.012","volume":"385","author":"M Zibetti","year":"2018","unstructured":"Zibetti M, Angrisano S, Dematteis F, Artusi CA, Romagnolo A, Merola A, Lopiano L (2018) Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease. J Neurol Sci 385:105\u2013108. \n                    https:\/\/doi.org\/10.1016\/j.jns.2017.12.012","journal-title":"J Neurol Sci"},{"issue":"5","key":"9337_CR26","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1007\/s00415-018-8816-9","volume":"265","author":"A Tessitore","year":"2018","unstructured":"Tessitore A, Marano P, Modugno N, Pontieri FE, Tambasco N, Canesi M, Latorre A, Lopiano L, Sensi M, Quatrale R, Solla P, Defazio G, Melzi G, Costanzo AM, Gualberti G, di Luzio Paparatti U, Antonini A (2018) Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study. J Neurol 265(5):1124\u20131137. \n                    https:\/\/doi.org\/10.1007\/s00415-018-8816-9","journal-title":"J Neurol"},{"issue":"3","key":"9337_CR27","first-page":"147","volume":"27","author":"G Abbruzzese","year":"2012","unstructured":"Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Antonini A (2012) Continuous intestinal infusion of levodopa\/carbidopa in advanced Parkinson\u2019s disease: efficacy, safety and patient selection. Funct Neurol 27(3):147\u2013154","journal-title":"Funct Neurol"},{"issue":"10","key":"9337_CR28","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/mds.22596","volume":"24","author":"H Honig","year":"2009","unstructured":"Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chauduri KR (2009) Intrajejunal levodopa infusion in Parkinson\u2019s disease. A pilot multicenter study of effects on non motor symptoms and quality of life. Mov Disord 24(10):1468\u20131474.","journal-title":"Mov Disord"},{"issue":"5","key":"9337_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/WNF.0b013e3182613dea","volume":"35","author":"P Reddy","year":"2012","unstructured":"Reddy P, Martinez-Martin P, Rizos A, Martin A, Faye GC, Forgacs I, Odin P, Antonini A, Chaudhuri KR (2012) Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin Neuropharmacol 35(5):205\u2013217","journal-title":"Clin Neuropharmacol"},{"key":"9337_CR30","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/npjparkd.2016.15","volume":"2","author":"HH Fernandez","year":"2016","unstructured":"Fernandez HH, Robieson WZ, Chatamra K, Dubow J, Eaton S, Benesh JA, Odin P (2016) Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson's disease. NPJ Parkinsons Dis 2:16015. \n                    https:\/\/doi.org\/10.1038\/npjparkd.2016.15\n                    \n                  \n                           eCollection 2016","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"9337_CR31","first-page":"79","volume":"16","author":"A Fasano","year":"2012","unstructured":"Fasano A, Ricciardi L, Lena F, Bentivoglio AR, Modugno N (2012) Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. Eur Rev Med Pharmacol Sci. 16(1):79\u201389","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"9337_CR32","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1111\/ane.12075","volume":"127","author":"M Zibetti","year":"2013","unstructured":"Zibetti M, Rizzone M, Merola A, Angrisano S, Rizzi L, Montanaro E, Cicolin A, Lopiano L (2013) Sleep improvement with levodopa\/carbidopa intestinal gel infusion in Parkinson disease. Acta Neurol Scand 127(5):e28\u2013e32. \n                    https:\/\/doi.org\/10.1111\/ane.12075","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"9337_CR33","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00415-017-8491-2","volume":"264","author":"M Zibetti","year":"2017","unstructured":"Zibetti M, Romagnolo A, Merola A, Priano L, Montanaro E, Angrisano S, Tribolo A, Cicolin A, Lopiano L (2017) A polysomnographic study in parkinsonian patients treated with intestinal levodopa infusion. J Neurol. 264(6):1085\u20131090. \n                    https:\/\/doi.org\/10.1007\/s00415-017-8491-2","journal-title":"J Neurol"},{"key":"9337_CR34","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/mdc3.12640","volume":"25;5(5)","author":"V Rispoli","year":"2018","unstructured":"Rispoli V, Golfr\u00e8 Andreasi N, Penna G, Preda F, Contini E, Sensi M (2018) Levodopa\/carbidopa intestinal gel infusion therapy: focus on gait and balance. Mov Disord Clin Pract 25;5(5):542\u2013545. \n                    https:\/\/doi.org\/10.1002\/mdc3.12640","journal-title":"Mov Disord Clin Pract"},{"issue":"9","key":"9337_CR35","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s10072-015-2234-x","volume":"36","author":"G Cossu","year":"2015","unstructured":"Cossu G, Ricchi V, Pilleri M, Mancini F, Murgia D, Ricchieri G, Mereu A, Melis M, Antonini A (2015) Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with \"on\" freezing of gait. Neurol Sci. 36(9):1683\u20131686. \n                    https:\/\/doi.org\/10.1007\/s10072-015-2234-x","journal-title":"Neurol Sci"},{"issue":"4","key":"9337_CR36","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/mds.26485","volume":"31","author":"AE Lang","year":"2016","unstructured":"Lang AE, Rodriguez RL, Boyd JT, Chouinard S, Zadikoff C, Espay AJ, Slevin JT, Fernandez HH, Lew MF, Stein DA, Odin P, Fung VS, Klostermann F, Fasano A, Draganov PV, Schmulewitz N, Robieson WZ, Eaton S, Chatamra K, Benesh JA, Dubow J (2016) Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Mov Disord. 31(4):538\u2013546. \n                    https:\/\/doi.org\/10.1002\/mds.26485","journal-title":"Mov Disord"},{"key":"9337_CR37","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1212\/WNL.0000000000001500","volume":"84","author":"D Calandrella","year":"2015","unstructured":"Calandrella D, Romito LM, Elia AE, Del Sorbo F, Bagella CF, Falsitta M, Albanese A (2015) Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease. Neurology 84:1669\u20131672","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09337-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09337-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09337-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T23:12:24Z","timestamp":1590448344000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09337-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,27]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["9337"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09337-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,27]]},"assertion":[{"value":"22 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Angelo Antonini has received compensation for consultancy and speaker-related activities from UCB, Boehringer Ingelheim, AbbVie, Zambon, Bial, Lundbeck; he receives research support from Chiesi Pharmaceuticals, Lundbeck, Horizon 2020 - PD_Pal Grant 825785, Ministry of Education University and Research (MIUR) Grant ARS01_01081. He serves as consultant for Boehringer\u2013Ingelheim for legal cases on pathological gambling. Graziano Gusmaroli, Pietro Marano, Nicola Modugno, Rocco Quatrale, Mariachiara Sensi, Paolo Solla, and Filippo Tamma have received honoraria for consulting services and symposia from AbbVie. Leonardo Lopiano has received honoraria for consulting services and symposia from AbbVie, Zambon, UCB, DOC, Chiesi, and Bial. Francesca Mancini has received honoraria for consulting services and symposia from AbbVie and Zambon. Roberto Eleopra has received compensation for consultancy and speaker-related activities from Ipsen SpA, Boston Scientific, BrainLab Germany. Rocco Quatrale has received compensation for consultancy and speaker from AbbVie and Zambon. Annarita Bentivoglio received honorarium for participation in advisory board from Merz and AbbVie and has received compensation for speaker-related activities from AbbVie, UCB, Lundbeck, Bial, Neuroderm, Zambon, Allergan, Ipsen. Roberta Zangaglia has received honoraria for speaker-related activities from AbbVie and Boston Scientific. Giuseppe Meco has nothing to disclose. Giuliana Gualberti and Gabriella Melzi are employees of AbbVie Italy and may own AbbVie stocks\/options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The protocol of the study was approved by the Ethics Committee of each local health authority and each patient provided informed consent. The study was conducted in accordance with the principles of the International Conference on Harmonization Good Clinical Practices.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}